Abstract: Off-Label Prescribing of Quetiapine in the US Using a Large Real-Time Pharmacy Claims Database

 

Abstract: Off-Label Prescribing of Quetiapine in the US Using a Large Real-Time Pharmacy Claims Database

Second-generation anti-psychotic medication use has increased dramatically, although the prevalence of the indicated psychiatric conditions (bipolar, schizophrenia) has remained stable The potential harm from off-label prescribing for mild conditions that have little evidence to support them (i.e., anxiety, insomnia) warrants monitoring. This study explore trends in off-label prescribing of sub-therapeutic quetiapine doses (<= 25 mg) versus indicated therapeutic doses of 400-800 mg between 2013 and early 2016.